sulbactam has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arend, LNVS; Chaiben, V; Dantas, LR; de Andrade, AP; Ribeiro, VST; Suss, PH; Telles, JP; Tuon, FF; Yamada, CH | 1 |
| Busch, DH; Dommasch, M; Feihl, S; Heim, M; Lahmer, T; Lukas, M; Querbach, C; Rothe, K; Schmid, RM; Schneider, G; Schneider, J; Spinner, CD; Treiber, M; Wallnöfer, F; Waschulzik, B; Wurst, M; Zink, A | 1 |
| Akat, H; Laloglu, F; Orbak, Z | 1 |
3 other study(ies) available for sulbactam and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A carbapenem-resistant Acinetobacter baumannii outbreak associated with a polymyxin shortage during the COVID pandemic: an in vitro and biofilm analysis of synergy between meropenem, gentamicin and sulbactam.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; Biofilms; COVID-19; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Pandemics; Polymyxins; Sulbactam | 2022 |
Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Antifungal Agents; Antimicrobial Stewardship; Aspergillosis; Azithromycin; Bacterial Infections; Cohort Studies; Coinfection; COVID-19; Enterobacteriaceae Infections; Escherichia coli Infections; Female; Germany; Humans; Klebsiella Infections; Linezolid; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; Retrospective Studies; SARS-CoV-2; Staphylococcal Infections; Streptococcal Infections; Sulbactam; Vancomycin; Young Adult | 2021 |
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Topics: Ampicillin; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Drug Combinations; Enoxaparin; Humans; Hydroxychloroquine; Hypoxia; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Lung; Male; Mucocutaneous Lymph Node Syndrome; Oseltamivir; Oxygen Inhalation Therapy; Ritonavir; Sulbactam; Tomography, X-Ray Computed | 2021 |